Antonio Carlo Bossi (Antonio Bossi, Antonio C Bossi)

ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 15

Top Venues

Human vaccines & immunotherapeutics

Diabetes therapy : research, treatment and education of diabetes and related disorders

BMJ open diabetes research & care

Acta diabetologica

ASST Bergamo Ovest

Università degli Studi (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

ASST Bergamo Ovest Apr 01 2012

Italy

Director Endocrine Diseases and Diabetes Regional Centre :: Medical Science

Azienda Ospedaliera Treviglio Caravaggio Mar 31 2011 - Oct 31 2012

Italy

Head Department Internal Medicine :: Internal Medicine

Azienda Ospedaliera Treviglio Caravaggio Jan 01 2001 - Mar 01 2011

Italy

Director Metabolic Diseases and Diabetes Unit :: Internal Medicine

Azienda Ospedaliera Treviglio Caravaggio Jan 01 1991 - Dec 31 2000

Italy

Deputy Director Internal Medicine :: Internal Medicine

Azienda Ospedaliera Treviglio Caravaggio Oct 16 1987 - Dec 31 1990

Italy

Assistant :: Internal Medicine

IRCCS Policlinico San Donato Dec 01 1981 - Oct 15 1987

Italy

Assistant :: Internal Medicine

Education History

Università degli Studi Nov 04 1973 - Nov 29 1979

Italy

PHD

Publications

Maria Elena Malighetti, Laura Molteni, Emanuela Orsi, Roberta Serra, Alessia Gaglio, Federica Mazzoleni, Filomena Russo, Antonio Carlo Bossi
IDegLira improves time in range in a cohort of patients with type 2 diabetes: TiREX study. Acta diabetologica (2024)
Walter Vena, Stella Pigni, Nazarena Betella, Annalisa Navarra, Giuseppe Favacchio, Giovanna Mantovani, Andrea Gerardo Lania, Antonio Carlo Bossi
COVID-19 vaccines and blood glucose control: Friend or foe? Human vaccines & immunotherapeutics 20 (1) (2024)
Walter Vena, Stella Pigni, Nazarena Betella, Annalisa Navarra, Giuseppe Favacchio, Giovanna Mantovani, Andrea Gerardo Lania, Antonio Carlo Bossi
COVID-19 vaccines and blood glucose control: Friend or foe? Human vaccines & immunotherapeutics 20 (1) (2024)
Walter Vena, Stella Pigni, Nazarena Betella, Annalisa Navarra, Giuseppe Favacchio, Giovanna Mantovani, Andrea Gerardo Lania, Antonio Carlo Bossi
COVID-19 vaccines and blood glucose control: Friend or foe? Human vaccines & immunotherapeutics 20 (1) (2024)
Walter Vena, Stella Pigni, Nazarena Betella, Annalisa Navarra, Giuseppe Favacchio, Giovanna Mantovani, Andrea Gerardo Lania, Antonio Carlo Bossi
COVID-19 vaccines and blood glucose control: Friend or foe? Human vaccines & immunotherapeutics 20 (1) (2024)
Annalisa Natalicchio, Camilla Sculco, Gianni Belletti, Martina Fontanelli, Carlotta Galeone, Antonio Carlo Bossi
Patient-Support Program in Diabetes Care During the Covid-19 Pandemic: An Italian Multicentric Experience. Patient preference and adherence 16 (2022)
Piero Ruggenenti, Monica Cortinovis, Aneliya Parvanova, Matias Trillini, Ilian P Iliev, Antonio Carlo Bossi, Antonio Belviso, Maria C Aparicio, Roberto Trevisan, Stefano Rota, Annalisa Perna, Tobia Peracchi, Nadia Rubis, Davide Martinetti, Silvia Prandini, Flavio Gaspari, Fabiola Carrara, Salvatore De Cosmo, Giancarlo Tonolo, Ruggero Mangili, Guiseppe Remuzzi, null null
Preventing microalbuminuria with benazepril, valsartan, and benazepril-valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study. PLoS medicine 18 (7) (2021)
Fabiola Carrara, Piero Ruggenenti, Annalisa Perna, Ilian Petrov Iliev, Flavio Gaspari, Silvia Ferrari, Nadia Stucchi, Antonio Carlo Bossi, Roberto Trevisan, Guiseppe Remuzzi, Aneliya Parvanova
Glomerular resistances predict long-term GFR decline in type 2 diabetic patients without overt nephropathy: a longitudinal subgroup analysis of the DEMAND trial. Acta diabetologica (2021)
Antonio Carlo Bossi, Valentina De Mori, Carlotta Galeone, Davide Pietro Bertola, Margherita Gaiti, Annalisa Balini, Denise Berzi, Franco Forloni, Giancarla Meregalli, Federica Turati
PERsistent Sitagliptin treatment & Outcomes (PERS&O 2.0) study, long-term results: a real-world observation on DPP4-inhibitor effectiveness. BMJ open diabetes research & care 8 (1) (2021)
Antonio Carlo Bossi, Franco Forloni, Paolo Luigi Colombelli
Lack of Efficacy of SGLT2-i in Severe Pneumonia Related to Novel Coronavirus (nCoV) Infection: No Little Help from Our Friends. Diabetes therapy : research, treatment and education of diabetes and related disorders 11 (7) (2020)
Antonio Carlo Bossi, Franco Forloni, Paolo L Colombelli
A Response To: Sodium-Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions. Diabetes therapy : research, treatment and education of diabetes and related disorders 11 (12) (2020)
Antonio Carlo Bossi, Valentina De Mori, Cristiana Scaranna, Giovanni Veronesi, Giuseppe Lepore, null null
ANDREW: A Multicenter, Prospective, Observational Study in Patients with Type 2 Diabetes on Persistent Treatment with Dulaglutide. Diabetes therapy : research, treatment and education of diabetes and related disorders 11 (11) (2020)
Marilena Vitale, Maria Masulli, Angela Albarosa Rivellese, Enzo Bonora, Anna Carla Babini, Giovanni Sartore, Laura Corsi, Raffaella Buzzetti, Giuseppe Citro, Maria Pompea Antonia Baldassarre, Antonio Carlo Bossi, Carla Giordano, Stefania Auciello, Elisabetta Dall'Aglio, Rossella Iannarelli, Laura Tonutti, Michele Sacco, Graziano Di Cianni, Gennaro Clemente, Giovanna Gregori, Sara Grioni, Vittorio Krogh, Gabriele Riccardi, Olga Vaccaro
Pasta Consumption and Connected Dietary Habits: Associations with Glucose Control, Adiposity Measures, and Cardiovascular Risk Factors in People with Type 2 Diabetes-TOSCA.IT Study. Nutrients 12 (1) (2019)
Antonio Carlo Bossi
Comment on Muraki et al. Potato Consumption and Risk of Type 2 Diabetes: Results From Three Prospective Cohort Studies. Diabetes Care 2016;39:376-384. Diabetes care 39 (9) (2018)
Giulia Buonaiuto, Valentina De Mori, Alessandra Braus, Annalisa Balini, Denise Berzi, Rita Carpinteri, Franco Forloni, Giancarla Meregalli, Gian Luca Ronco, Antonio Carlo Bossi
PERS&O (PERsistent Sitagliptin treatment & Outcomes): observational retrospective study on cardiovascular risk evolution in patients with type 2 diabetes on persistent sitagliptin treatment. BMJ open diabetes research & care 4 (1) (2016)

Antonio Carlo Bossi.css-eqlu8i{font-size:small;padding-left:4px;} (Antonio Bossi, Antonio C Bossi)

Publication Activity (10 Years)

Top Topics

Top Venues

Antonio Carlo Bossi (Antonio Bossi, Antonio C Bossi)